Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 14/20 | 0.56 |
| ▸ | RARG | P13631 | 13/20 | 0.56 |
| ▸ | RARA | P10276 | 11/20 | 0.56 |
| ▸ | RARB | P10826 | 11/20 | 0.56 |
| ▸ | CYP26A1 | O43174 | 4/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | GMNN | O75496 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | THPO | P40225 | 1/20 | 0.56 |
| ▸ | MTOR | P42345 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6950912 | 1.00 | RXRA (0.56) | RXRARARGRARARARBCYP26A1 | |
| SCHEMBL6950903 | 1.00 | RXRA (0.56) | RXRARARGRARARARBCYP26A1 | |
| SCHEMBL8796227 | 0.86 | RXRA (0.55) | RXRARARGRARARARBCYP26A1 | |
| SCHEMBL8796223 | 0.86 | RXRA (0.55) | RXRARARGRARARARBCYP26A1 | |
| SCHEMBL8796229 | 0.86 | RXRA (0.55) | RXRARARGRARARARBCYP26A1 | |
| Bromide SCHEMBL9064208 | 0.84 | RXRA (0.53) | RXRARARGRARARARBCYP26A1 | |
| Bromide SCHEMBL9064204 | 0.84 | RXRA (0.53) | RXRARARGRARARARBCYP26A1 | |
| SCHEMBL8338805 | 0.83 | RXRA (0.61) | RXRARARGRARARARBCYP26A1 | |
| SCHEMBL8904248 | 0.83 | RXRA (0.61) | RXRARARGRARARARBCYP26A1 | |
| SCHEMBL8845981 | 0.80 | RARG (0.58) | RXRARARGRARARARBCYP26A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115010577-A | Compounds and synthetic methods for the preparation of retinoid X receptor-specific retinoids | IO治疗公司 | 2022-09-06 | — | — | CN | claimed |
| US-10919835-B2 | Compounds and synthetic methods for the preparation of retinoid X receptor-specific retinoids | Io Therapeutics, Inc. (US) | 2021-02-16 | — | — | US | claimed |
| US-20200190008-A1 | COMPOUNDS AND SYNTHETIC METHODS FOR THE PREPARATION OF RETINOID X RECEPTOR-SPECIFIC RETINOIDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-06-18 | — | — | US | claimed |
| CN-115010577-A | Compounds and synthetic methods for the preparation of retinoid X receptor-specific retinoids | IO治疗公司 | 2022-09-06 | — | — | CN | disclosed |
| CN-111465402-B | Compounds and synthetic methods for the preparation of retinoid X receptor-specific retinoids | IO治疗公司 | 2022-05-24 | — | — | CN | disclosed |
| US-20210139404-A1 | COMPOUNDS AND SYNTHETIC METHODS FOR THE PREPARATION OF RETINOID X RECEPTOR-SPECIFIC RETINOIDS | Io Therapeutics, Inc. | 2021-05-13 | — | — | US | disclosed |
| US-20210139404-A1 | COMPOUNDS AND SYNTHETIC METHODS FOR THE PREPARATION OF RETINOID X RECEPTOR-SPECIFIC RETINOIDS | Io Therapeutics, Inc. | 2021-05-13 | — | — | US | disclosed |
| US-10919835-B2 | Compounds and synthetic methods for the preparation of retinoid X receptor-specific retinoids | Io Therapeutics, Inc. (US) | 2021-02-16 | — | — | US | disclosed |
| US-10919835-B2 | Compounds and synthetic methods for the preparation of retinoid X receptor-specific retinoids | Io Therapeutics, Inc. (US) | 2021-02-16 | — | — | US | disclosed |
| EP-3710027-A1 | COMPOUNDS AND SYNTHETIC METHODS FOR THE PREPARATION OF RETINOID X RECEPTOR-SPECIFIC RETINOIDS | IO Therapeutics, Inc. (US) | 2020-09-23 | — | — | EP | disclosed |
| CN-111465402-A | Compounds and synthetic methods for the preparation of retinoid X receptor-specific retinoids | IO治疗公司 | 2020-07-28 | — | — | CN | disclosed |
| EP-0848696-A1 | 2,4-PENTADIENOIC ACID DERIVATIVES HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | Allergan (US) | 1998-06-24 | — | — | EP | disclosed |
| US-5675033-A | FOR TREATMENT OF SKIN DISORDERS | ALLERGAN (US) | 1997-10-07 | — | — | US | disclosed |
| US-5663367-A | REGULATOR OF CELL PROLIFERATION AND DIFFERENTIATION; TREATMENT OF SKIN DISORDERS, ANTIINFLAMMATORY AGENTS, ANTICARCINOGENIC AGENTS | ALLERGAN (US) | 1997-09-02 | — | — | US | disclosed |
| EP-0775103-A1 | RETINOIC ACID X-RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 1997-05-28 | — | — | EP | disclosed |
| EP-0629604-B1 | Alicyclic phospholipase A2 inhibitors | BRISTOL MYERS SQUIBB CO (US) | 1997-04-16 | — | — | EP | disclosed |
| WO-1996039374-A1 | 2,4-PENTADIENOIC ACID DERIVATIVES HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | ALLERGAN (US) | 1996-12-12 | — | — | WO | disclosed |
| WO-1996005165-A1 | RETINOIC ACID X-RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 1996-02-22 | — | — | WO | disclosed |
| US-5436369-A | Alicyclic phospholipase A2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-07-25 | — | — | US | disclosed |
| EP-0629604-A2 | Alicyclic phospholipase A2 inhibitors | Bristol-Myers Company (US) | 1994-12-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190008-A1 | COMPOUNDS AND SYNTHETIC METHODS FOR THE PREPARATION OF RETINOID X RECEPTOR-SPECIFIC RETINOIDS | RXRG, RXRB, RXRA | RXRA 3/4885RARG 4/4885RARA 6/4885 |
| US-10919835-B2 | Compounds and synthetic methods for the preparation of retinoid X receptor-specific retinoids | RXRG, RXRB, RXRA | RXRA 3/4885RARG 4/4885RARA 6/4885 |
| US-20210139404-A1 | COMPOUNDS AND SYNTHETIC METHODS FOR THE PREPARATION OF RETINOID X RECEPTOR-SPECIFIC RETINOIDS | RXRG, RXRB, RXRA | RXRA 3/4885RARG 4/4885RARA 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.